Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
Business Wire•04/11/2026•17:15 ET
0
Key Highlights
- ➤$1 billion share repurchase program authorized; $500 million expected by end-2026
- ➤Remaining repurchases planned during 2027, subject to market conditions
- ➤Tolga Tanguler departing Chief Commercialization Officer role
- ➤Executive search underway for Alnylam’s next Chief Commercialization Officer
Expert Statements
Amy Schulman, Chair of Alnylam’s Board of Directors
“Today we announced two important decisions, both of which demonstrate our conviction in Alnylam's future”
Amy Schulman, Chair of Alnylam’s Board of Directors
“Alnylam has a distinctive and robust scientific foundation, a strong commercial opportunity and a fulsome pipeline. We will continue to focus on translating those strengths into sustained performance and long-term value for shareholders. Today’s repurchase authorization reflects our confidence in that future and our commitment to disciplined capital allocation. We are committed to continuing to evaluate opportunities to build on Alnylam’s strengths and create value for our shareholders.”
Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam
“I'm grateful for Tolga’s leadership and the contributions he has made over the past several years”
Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam
“As we look ahead, we have significant opportunities to reach more patients with our medicines, advance our pipeline and continue building a sustainable, high-performing business.”
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
Board authorizes share repurchase program reflecting confidence in Alnylam's long-term growth prospects and commitment to disciplined capital allocation
Get started
Create a free account to read the full story.